Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
How would you approach a patient with osteoporosis who remains at risk for osteoporotic fracture and who had an atypical femur fracture on denosumab?
Related Questions
Are there any concerns with using denosumab in a patient with chronic hepatitis B infection on antiviral therapy?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
Is there any concern with starting romosozumab in a patient who is taking raloxifene for a history of breast cancer?
Is it safe to combine Prolia with other immunosuppressants?
Is it safe to continue administering Prolia per schedule for osteoporosis treatment shortly after a patient has undergone extensive spinal surgery?
Do you recommend adjusting the duration of a drug holiday based on the specific bisphosphonate used when treating osteoporosis?
Would you continue zolendronic acid infusions if the bone density decreases significantly in year two?
Is there any evidence regarding bone density gains/fracture reduction in the setting of treatment with romosozumab after a two year course of teriparatide?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
